On January 24, 2019, the Office of the Inspector General (OIG) for the federal Department of Health and Human Services (HHS) issued an advisory opinion that will allow Otsuka Pharmaceutical Co., Ltd (Otsuka) to loan smartphones to people taking Abilify MyCite, a digital medicine device. Abilify MyCite is the tablet form of the antipsychotic aripiprazole manufactured with an embedded ingestible sensor developed by Proteus Digital Health. The sensor records that the medication was taken, and via a wearable patch communicates that information to a mobile application. The system consists of the pill, a patch, an app for the consumer, and . . .
Restricted Content
You must be an Elite member to view this resource.
